Olaparib Response in Metastatic Breast Cancer: Tumor DNA and Biomarker Data

A clinical case study data record supports a manuscript reporting a patient's response to the PARP inhibitor olaparib. The data includes tumor DNA sequencing analysis and a biomarker time series, deposited in NCBI Sequence Read Archive under accession PRJNA635377. Sherko Kuemmel authored the related manuscript.

Use Cases

• Analyze mutant allele frequency patterns based on the tumor DNA next-generation sequencing data.
• Study copy number variations in metastatic breast cancer based on the NGS analysis spreadsheet.
• Track biomarker (CA 15-3) response to therapy over time based on the data underlying Figure 1.

Strengths

• Includes tumor DNA sequencing data with mutant allele frequency and copy number variation analysis.
• Provides specific NCBI Sequence Read Archive accession (PRJNA635377) for raw data.
• Contains a time series of the CA 15-3 biomarker linked to a published figure.

Limitations

• Germline DNA sequencing data is unavailable due to data protection laws.
• Row count and dataset scale are unknown, limiting suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.

Provenance

Source

NCBI Sequence Read Archive (PRJNA635377) and supplementary files from a published manuscript.

Collection Method

Clinical case study; tumor DNA sequenced via next-generation sequencing.